Beclomethasone/Formoterol vs Fluticasone/Salmeterol in COPDBeclomethasone/Formoterol vs Fluticasone/Salmeterol in COPD
Find out which inhaler combo is quicker on the draw -- for breath in patients with COPD. BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 20, 2014 Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news
GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD
In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist (also known as an anticholinergic), umeclidinium ‘UMEC’ 62.5mcg (IncruseTM Ellipta®) and UMEC 125mcg, to the inhaled corticosteroid and long-acting beta2 agonist combination medicine, fluticasone proprionate and salmeterol ‘FSC 250/50 mcg’ (Advair ® Diskus®), was evaluated in chronic obstructive pulmonary disease (COPD) patients over 12 weeks. (Source: GSK news)
Source: GSK news - May 19, 2014 Category: Pharmaceuticals Source Type: news
Novartis Reports Positive Ultibro Phase III Study Results For COPD
Novartis announced positive first results from the Phase III head to head LANTERN study. The study was comparing how once-daily Ultibro Breezhaler (indacaterol/glycopyrronium) improved lung function compared to twice-daily Seretide Accuhaler (salmeterol/fluticasone (SFC)) in patients with chronic obstruction pulmonary disease (COPD) with or without a history of moderate to severe exacerbations in the previous year. The trial met its primary and secondary endpoints, demonstrating Ultibro Breezhaler’s superiority over Seretide. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - May 2, 2014 Category: Pharmaceuticals Source Type: news
New Sleep Articles Available from April
This month brings a bouquet of articles meant to address seasonal allergies, so common as spring flowers bloom. Included in this collection are both over-the-counter and prescription options, pills and sprays that can be used to treat allergic rhinitis. Explore these options, including: Allegra, Claritin, Zyrtec, Singulair, Nasacort, Veramyst, and Zetonna. In addition, learn how a backpack might help you to prevent snoring and sleep apnea that occurs when sleeping on your back.
Read More:
How a Backpack Might Prevent Snoring and Sleep Apnea
Over-the-Counter Allegra Medication for Allergies
Over-the-Counter Claritin M...
Source: About Sleep Disorders - April 28, 2014 Category: Sleep Medicine Source Type: news
GSK and Theravance initiate Phase III trial of COPD combination drug FF/VI
GlaxoSmithKline (GSK) and Theravance have initiated a Phase III trial of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta2agonist (LABA), vilanterol (FF/VI) in patients with chronic obstructive pul… (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2014 Category: Pharmaceuticals Source Type: news
GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan
GlaxoSmithKline (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta2 agonist (LABA), vilanterol (FF/VI). (Source: GSK news)
Source: GSK news - April 22, 2014 Category: Pharmaceuticals Source Type: news
GSK completes patient enrolment in new pulmonary disease study
GlaxoSmithKline (GSK) and Theravance have announced the completion of patient enrolment in the SUMMIT trial designed to determine the impact of Relvar/Breo Ellipta (fluticasone furoate'FF'/vilanterol 'VI') in patients with moderate chronic obstructiv… (Source: Drug Development Technology)
Source: Drug Development Technology - March 17, 2014 Category: Pharmaceuticals Source Type: news
Vilanterol/Fluticasone, Lomitapide, and MipomersenVilanterol/Fluticasone, Lomitapide, and Mipomersen
Learn about a new inhalation product for COPD and 2 new agents for homozygous familial hypercholesterolemia. Journal of the American Pharmacists Association (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2014 Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news
GSK and Theravance report positive results from Phase III asthma study
GlaxoSmithKline (GSK) and Theravance have released positive results from a Phase III efficacy and safety trial of fluticasone furoate(FF)/vilanterol (VI) designed to support a potential filing for an asthma indication for adults in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - December 9, 2013 Category: Pharmaceuticals Source Type: news
GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate “FF”/vilanterol “VI”. (Source: GSK news)
Source: GSK news - December 6, 2013 Category: Pharmaceuticals Source Type: news
Breo Ellipta for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is a dry powder inhaler indicated for the long-term maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease… (Source: Drug Development Technology)
Source: Drug Development Technology - November 11, 2013 Category: Pharmaceuticals Source Type: news
GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma
GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler. (Source: GSK news)
Source: GSK news - October 23, 2013 Category: Pharmaceuticals Source Type: news
Generic Drugmaker Sees Obstacles to Copying Advair Before 2018Generic Drugmaker Sees Obstacles to Copying Advair Before 2018
Teva Pharmaceuticals does not expect to see the launch of generic copies of GlaxoSmithKline's best-selling drug Advair (fluticasone/salmeterol) that could be sold as a true substitute to U.S. patients before 2018. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
CHMP Backs Relvar Ellipta for Asthma, COPDCHMP Backs Relvar Ellipta for Asthma, COPD
A European Medicines Agency committee has recommended marketing authorization for fluticasone furoate/vilanterol for the treatment of asthma and COPD. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
RELVAR™ ELLIPTA™ receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone furoate/vilanterol (FF/VI) under the proposed brand name RELVAR™ ELLIPTA™ for; (Source: GSK news)
Source: GSK news - September 19, 2013 Category: Pharmaceuticals Source Type: news
